Compare DexCom, Inc. (DXCM) vs 8x8 Inc (EGHT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs 8x8 Inc — how do they compare? DexCom, Inc. trades at $84.14 (market cap $31.86B), while 8x8 Inc trades at $2.1 (market cap $311.98M). The key difference: DexCom, Inc. is far larger — about 102.1× 8x8 Inc's market cap, and DexCom, Inc. is trading nearer its 52-week high, 8x8 Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and 8x8 Inc for 16 Days on average.
| DXCM | EGHT | |
|---|---|---|
Market Cap | $31.86B | $311.98M |
Volume | 3,607,070 | 1,639,086 |
Sector | Health | Technology |
52-Week High | $92.34 | $2.76 |
52-Week Low | $54.84 | $1.59 |
Typical Hold Time | 62 Days | 16 Days |
Enterprise Value | $31.32B | $578.90M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $84.11, down 0.23% on the day, with a bearish technical signal but strong fundamental performance. The company reported Q2 2026 EPS of $0.70, beating expectations, and has shown consistent revenue growth, with 2025 revenue reaching $4.66 billion and net income of $836.3 million. Analyst consensus is strongly bullish with an 80.77% buy rating and a $95.07 price target. Recent news highlights growth opportunities in Type 2 diabetes care and key executive promotions.
The outlook for DXCM is positive due to robust earnings beats, expanding market opportunities, and strong institutional support. However, risks include competitive pressures, reimbursement challenges, and a high valuation with a P/E of 33.38. The stock presents a growth opportunity but requires monitoring of execution against these risks.
EGHT trades at $2.11, down 1.4% today, with a bullish technical signal supported by moving averages. The company shows improving fundamentals with three consecutive quarterly EPS beats and projected profitability in 2026. Recent news highlights cost-saving client wins and AI product growth, while analysts maintain a mixed consensus with a $19.77 price target representing significant upside potential.
The stock presents a high-risk, high-reward opportunity with strong revenue growth potential but faces challenges from negative net income and high debt levels. Key catalysts include continued earnings outperformance and AI platform adoption, while risks involve execution challenges and competitive pressures in the communications software sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About 8x8 Inc
8x8 is a provider of integrated cloud communications and contact center solutions. Its platform combines voice, video, chat, and contact center functionality into a single application to help businesses collaborate.
Read more on EGHT →
